Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1949 1
1951 2
1953 1
1954 7
1955 2
1956 3
1957 6
1958 7
1959 5
1960 1
1961 7
1962 6
1963 9
1964 8
1965 8
1966 13
1967 10
1968 7
1969 17
1970 11
1971 4
1972 8
1973 10
1974 7
1975 5
1976 10
1977 6
1978 16
1979 8
1980 13
1981 13
1982 12
1983 13
1984 11
1985 10
1986 11
1987 12
1988 24
1989 16
1990 7
1991 11
1992 17
1993 7
1994 17
1995 8
1996 13
1997 18
1998 13
1999 19
2000 21
2001 26
2002 23
2003 21
2004 21
2005 16
2006 15
2007 13
2008 15
2009 12
2010 19
2011 22
2012 17
2013 20
2014 26
2015 23
2016 22
2017 23
2018 21
2019 8
2020 19
2021 18
2022 29
2023 16
2024 11
2025 12
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

918 results

Results by year

Filters applied: . Clear all
Page 1
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Gastaldelli A, et al. Among authors: bray r. Lancet Diabetes Endocrinol. 2022 Jun;10(6):393-406. doi: 10.1016/S2213-8587(22)00070-5. Epub 2022 Apr 22. Lancet Diabetes Endocrinol. 2022. PMID: 35468325 Clinical Trial.
Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial.
Sattar N, Neeland IJ, Dahlqvist Leinhard O, Fernández Landó L, Bray R, Linge J, Rodriguez A. Sattar N, et al. Among authors: bray r. Lancet Diabetes Endocrinol. 2025 Jun;13(6):482-493. doi: 10.1016/S2213-8587(25)00027-0. Epub 2025 Apr 30. Lancet Diabetes Endocrinol. 2025. PMID: 40318682 Free article. Clinical Trial.
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, Milicevic Z, Urva S, Haupt A, Robins DA. Frias JP, et al. Among authors: bray r. Diabetes Obes Metab. 2020 Jun;22(6):938-946. doi: 10.1111/dom.13979. Epub 2020 Feb 11. Diabetes Obes Metab. 2020. PMID: 31984598 Free PMC article. Clinical Trial.
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á. Ludvik B, et al. Among authors: bray r. Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6. Lancet. 2021. PMID: 34370970 Clinical Trial.
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Battelino T, Bergenstal RM, Rodríguez A, Fernández Landó L, Bray R, Tong Z, Brown K. Battelino T, et al. Among authors: bray r. Lancet Diabetes Endocrinol. 2022 Jun;10(6):407-417. doi: 10.1016/S2213-8587(22)00077-8. Epub 2022 Apr 22. Lancet Diabetes Endocrinol. 2022. PMID: 35468321 Clinical Trial.
918 results